REG - Immupharma PLC - Simbec-Orion appointed as CRO

ImmuPharmaAnnouncement

19/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231219:nRSS2772Xa&default-theme=true

RNS Number : 2772X  Immupharma PLC  19 December 2023

19 December 2023

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

 

Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3
pivotal study |

 Compelling findings on P140's MOA

 

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, is pleased to announce key updates on its late stage P140
(Lupuzor™) program, in patients with systemic lupus erythematosus
("SLE/Lupus").

 

Highlights

 

·    Simbec-Orion has been appointed as the Contract Research Organisation
("CRO"), for the P140 (Lupuzor™) Phase 3 study in SLE, following extensive
due-diligence and a six month tender process, involving 3 different CROs. This
was conducted by ImmuPharma's clinical team and agreed with its US partner,
Avion Pharmaceuticals, LLC ("Avion")

 

·    In addition, ImmuPharma and Avion consider that a Phase 3
dose-ranging study, rather than the longer Phase 2/3 adaptive study is
preferable. The direct Phase 3 route is faster to filing for approval whilst
also incorporating FDA's request for demonstration of a dose-ranging in the
pivotal program.

 

·    The international Phase 3 dose-ranging study design and protocol is
substantially different from previous clinical trials completed by ImmuPharma.
Dosing will still be a subcutaneous injection, once a month, but with
significantly higher doses, which have demonstrated safety and tolerability as
part of the clinical program. Two planned interim analyses during the course
of the study will allow early indications of the effectiveness of P140.

 

·    Recent further insights into P140's mechanism of action ("MOA")
supports its position as the only non-immunosuppressing molecule in clinical
development in the industry. A new potential standard of care for SLE
sufferers.

 

·    As the study continues to move forward in 2024, further details on
the study's timings, protocol and key elements of the clinical trial design
will be communicated at regular intervals.

 

 

 

Appointment of Simbec-Orion as CRO

 

Simbec-Orion, is an experienced, full-service Contract Research Organisation,
with offices across UK, Europe, and the United States, specialising in Rare
& Orphan conditions. Simbec-Orion has previous direct experience in Lupus
trials including conducting ImmuPharma's last Phase 3 study completed in 2018
and more recently conducted ImmuPharma's Pharmacokinetics ("PK") study
completed in 2022.

 

P140 (Lupuzor™) New study dosing , design and MOA

 

The whole P140 program was re-examined in 2021, and the Board decided that it
required a completely different approach, not only to commence a new Phase 3
study in Lupus, but also to be clear on the product offering and target
product profile. The three pillars of strength and confidence in our new
program are dose, design and MOA.

 

Dose

After three FDA guidance meetings, further human and animal pharmacokinetics
studies and reconciliation with efficacy demonstrated in the animal models, it
was concluded that the previous dose used in clinical studies was too low. The
new Phase 3 study will include dose-ranging up to 15 times higher than the
original study dose of 200 micrograms.

 

Design

The design of the pivotal Phase 3 study includes a dose-range. This design is
faster to complete than a Phase 2/3 adaptive study, while at the same time
incorporating all the key objectives. We confidently expect the efficacious
dose to be within this dose-range and we expect no adverse events that could
lead to product label warnings seen with all other approved drugs and standard
of care, which are all immunosuppressants. The study design allows two interim
analyses, so there will be short term updates on clinical activity of the
drug. P140 is not an immunosuppressant, so a key objective will be to taper
the use of steroids which are currently standard of care. The study will also
include analysis of certain biomarkers in relation to efficacy.

 

MOA

The lack of immunosuppression is explained by our refined MOA. All other
molecules in development possess varying degrees of immunosuppression, which
give rise to side effects and limit the dose that can be used to achieve
efficacy.

 

New evidence shows that P140 restores the tolerance systems by enabling
tolerogenic antigen presenting cells (like dendritic cells) to function
properly. As malfunction of the tolerance systems seems to be the root cause
of most if not all autoimmune diseases, it explains why P140 is so broadly
efficient across most autoimmune indications in animal models. P140 is the
only non-immunosuppressive molecule in the industry in clinical development
for the treatment of SLE.

 

This distinction sets the stage for a new gold standard therapy, conveniently
self-administered by the patient, once a month, which is safe and well
tolerated unlike standard of care or any other molecule in development which
are all immunosuppressants with significant safety warnings.

 

Further details on the protocol and key elements of the clinical trial design
will be communicated, once the details of the trial are available on
clinicaltrials.gov (a comprehensive database of privately and publicly funded
clinical studies conducted around the world).

 

Commenting on the announcement, Tim McCarthy, CEO of ImmuPharma, said:

 

"It has taken longer than we anticipated to fully appraise the three CROs
involved in the tender process, however,  we were determined to ensure that
we chose the most effective organisation that encompassed the high level
clinical expertise required to ensure the highest probability of success for
this trial. We are confident that Simbec-Orion meets our criteria.

 

Most importantly, following further detailed analysis of the protocol of this
study; new insights into the MOA of P140, combined with the outstanding safety
profile of the drug, we have compelling evidence that moving directly into a
pivotal Phase 3 study, is the most appropriate route forward and as a result,
we have a high level of confidence of the success of this study.

 

The second half of this year has been an extremely busy but focused period for
the team and I acknowledge the frustration of  shareholders for the
protracted period of time to reach the decision on the appointment of the CRO.
I thank everyone for their continued patience. We look forward to providing
further updates on the progress of this study, together with progress on CIDP
and our earlier stage programs."

 

Commenting further, Art Deas, CEO of Avion said:

"We continue to be excited by the potential of P140 and we look forward to
working closely with ImmuPharma and Simbec-Orion, to develop this potentially
life changing treatment for Lupus patients."

 

Fabrice Chartier, CEO of Simbec-Orion, further added:

"P140 is one of the most revolutionary and unique new drugs in development for
SLE and we are delighted to have been appointed to conduct this Phase 3
study."

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (https://www.immupharma.co.uk/) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 203 650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

Lupuzor™ MOA

 

The lack immunosuppression is explained by our refined MOA. All other
molecules in development possess varying degrees of immunosuppression, which
give rise to side effects and limit the dose that can be used to achieve
efficacy.

 

New evidence shows that P140 restores the tolerance systems by enabling
tolerogenic antigen presenting cells (like dendritic cells) to function
properly. As malfunction of the tolerance systems seems to be the root cause
of most if not all autoimmune diseases, it explains why P140 is so broadly
efficient across most autoimmune indications in animal models. P140 is the
only non-immunosuppressive molecule in the industry in clinical development
for the treatment of SLE.

 

This distinction sets the stage for a new gold standard therapy, conveniently
self-administered by the patient, once a month, which is safe and well
tolerated unlike standard of care or any other molecule in development which
are all immunosuppressants with significant safety warnings.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(https://www.immupharma.co.uk/)

 

About Avion Pharmaceuticals LLC

Avion Pharmaceuticals, LLC, is a specialty pharmaceutical company formed to
develop, acquire and market a portfolio of innovative pharmaceutical products
in the Women's Health and other therapeutic categories aligned with its
mission to improve the quality of patient lives. Avion Pharmaceuticals focuses
on identifying opportunities to develop, acquire and enhance the market
potential of innovative, commercially available therapeutics and late-stage
development drugs to fulfil unmet medical needs.

For more information, visit www.avionrx.com (https://www.avionrx.com/)

About Simbec-Orion

Simbec-Orion, is an experienced, full-service Contract Research Organisation ,
with offices across the UK, Europe, and the United States. Established for
over 45 years, and leveraging deep experience delivering first in human
(https://www.simbecorion.com/service/phase-1/)  clinical trials, providing
bespoke clinical trial services to small to mid-sized biotech and
pharmaceutical partners across Europe, North America and beyond. Across the
organisation scientific teams leverage both a wide therapeutic experience in
clinical pharmacology, such as CNS, respiratory, dermatology, vaccines and
anti-infectives, to more specialist expertise in Phase I-IV rare disease
(https://www.simbecorion.com/service/rare-diseases/)  and oncology
(https://www.simbecorion.com/service/oncology/) .

For more information, visit www.simbecorion.com (http://www.simbecorion.com)

About Lupus (Systemic Lupus Erythematosus / SLE)

 

Lupus is a chronic inflammatory disease which is thought to affect some 5
million individuals worldwide. The current standard of care still consists of
steroid and anti-malarial therapies which many have side-effects and poor
response in many patients. Recently more targeted monoclonal therapies are
GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There
still exists a high unmet medical need for a drug that has a strong efficacy
and safety profile.

 

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFEEFLLALIV